<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0503245018
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Ecinq
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ULIPRISTAL ACETATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        OTC
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        51.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Haupt Pharma M&#xFC;nster GmbH " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Haupt Pharma Münster GmbH 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Aspen Healthcare
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G03AD02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1.&nbsp; What Ecinq is and what it is used for</strong></p><p><u>Ecinq is an emergency contraceptive</u></p><p>Ecinq is indicated for emergency contraception within 120 hours (5 days) of unprotected sexual intercourse or contraceptive failure. Ecinq is not intended for routine use as a contraceptive. For example:</p><ul><li>if you had sexual intercourse without protection;</li><li>&nbsp;if your or your partner&rsquo;s condom tore, slipped or came off, or if you forgot to use one;</li><li>if you did not take your contraceptive pill as recommended.</li></ul><p>This is because the sperm can survive up to 5 days in your body after intercourse.</p><p>This medicine is suitable for any woman of childbearing age, including adolescents.</p><p>You can take this tablet at any time in the menstrual cycle.</p><p><u>Ecinq does not work if you are already pregnant.</u></p><p>If your menstrual period is late, there is a possibility that you may be pregnant. When your period is late or when you have symptoms of pregnancy (heavy breasts, morning sickness) you should consult a doctor or other healthcare professional before taking the tablet.</p><p>If you have unprotected sexual intercourse after taking the tablet, it will not stop you from becoming pregnant.</p><p>Unprotected sexual intercourse at any time during your cycle can lead to pregnancy.</p><p><u>Ecinq is not to be used for regular contraception</u></p><p>If you do not have a regular method of contraception, talk to your doctor or healthcare professional to choose one that is suitable for you.</p><p><u>How Ecinq works</u></p><p>Ecinq contains the substance <em>ulipristal acetate </em>which acts by modifying the activity of the natural hormone progesterone which is necessary for ovulation to occur. As a result, this medicine works by postponing ovulation. Emergency contraception is not effective in every case. Of 100 women who take this medicine approximately 2 will become pregnant.</p><p>This medicine is a contraceptive used to prevent a pregnancy from starting. If you are already pregnant, it will not interrupt an existing pregnancy.</p><p><u>Emergency contraception does not protect against sexually transmitted infections</u></p><p>Only condoms can protect you from sexually transmitted infections. This medicine will not protect you against HIV infection or any other sexually transmitted diseases (e.g. chlamydia, genital herpes, genital warts, gonorrhoea, hepatitis B and syphilis). Ask a healthcare professional for advice if you are worried about this.</p><p>There is more information about contraception at the end of this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>2.&nbsp; What you need to know before you take Ecinq </strong></p><p><strong>Do not take Ecinq</strong></p><ul><li>If you are allergic to ulipristal acetate or any of the other ingredients of this medicine (listed in section 6).</li></ul><p><strong>Warning and precautions</strong></p><p>Talk to your pharmacist, doctor or other healthcare professional before taking this medicine:</p><ul><li>if your period is late or you have symptoms of pregnancy (heavy breasts, morning sickness), as you may already be pregnant (see section &ldquo;Pregnancy, breast-feeding and fertility<em>&rdquo;)</em>;</li><li>if you suffer from severe asthma;</li><li>if you suffer from severe liver disease.</li></ul><p>Ulipristal acetate 30 mg is for occasional use only. It should never be used in place of a regular contraceptive method. Cases of serious liver injury and liver failure (requiring transplantation in some cases) have been reported with prolonged exposure to Ulipristal Acetate.</p><p>In all women, emergency contraception should be taken as soon as possible after unprotected intercourse. There is some evidence that this medicine may be less effective with increasing body weight or body mass index (BMI), but these data were limited and inconclusive. Therefore, Ecinq is still recommended for all women regardless of their weight or BMI.</p><p>You are advised to speak to a healthcare professional if you are concerned about any problems related to taking emergency contraception.</p><p>If you become pregnant despite taking this medicine, it is important that you see your doctor. See section &ldquo;Pregnancy, breast-feeding and fertility&rdquo; for more information.</p><p><strong>Other contraceptives and Ecinq</strong></p><p>This medicine may make regular hormonal contraceptives, like pills and patches, temporarily less effective.</p><p>If you are currently taking hormonal contraception, continue to use it as usual after taking the tablet, but be sure to use condoms every time you have sexual intercourse until your next period.</p><p>Do not use Ecinq together with another emergency contraceptive pill that contains levonorgestrel. By taking them both together, you might make this medicine less effective.</p><p><strong>Other medicines and Ecinq</strong></p><p>Tell your pharmacist, doctor or other healthcare professional if you are taking or have recently taken any other medicines, including medicines obtained without a prescription or herbal medicines.</p><p>Some medicines may prevent Ecinq from working effectively. If you have used any of the medicines listed below during the last 4 weeks, Ecinq may be less suitable for you. Your doctor may prescribe another type of (non-hormonal) emergency contraceptive, i.e. a copper intrauterine device (Cu-IUD):</p><ul><li>medicines used to treat epilepsy (for example, primidone, phenobarbital, phenytoin, fosphenytoine, carbamazepine, oxcarbazepine and barbiturates)</li><li>medicines used to treat tuberculosis (for example, rifampicin, rifabutin)</li><li>a treatment for HIV (ritonavir, efavirenz, nevirapine)</li><li>a medicine used to treat fungal infections (griseofulvin)</li><li>herbal remedies containing St John&#39;s wort (<em>Hypericum perforatum</em>).</li></ul><p>Speak to your doctor or pharmacist before using Ecinq when you use (or have recently used) any of the medicines stated above.</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p><em><u>Pregnancy</u></em></p><p>Before taking this medicine, if your period is late, tell your pharmacist, doctor or other healthcare professional, or do a pregnancy test in order to make sure you are not already pregnant (see section <em>&ldquo;</em>Warning and precautions&rdquo;).</p><p>This medicine is a contraceptive used to prevent a pregnancy from starting. If you are already pregnant it will not interrupt an existing pregnancy.</p><p>If you become pregnant despite taking Ecinq, you are encouraged to ask your doctor to register your pregnancy in an official registry. Sharing your information may help women in the future understand the safety or risks of Ecinq during a pregnancy.</p><p><em><u>Breast-feeding</u></em></p><p>If you take this medicine while you are breastfeeding a baby, do not breast-feed for one week after taking Ecinq. During this time, it is recommended to use a breast pump in order to maintain milk production but throw away your breast milk. The effect of breastfeeding your baby in the week after taking this medicine is not known.</p><p><em><u>Fertility</u></em></p><p>This medicine will not affect your future fertility. If you have unprotected sexual intercourse after taking this medicine, it will not stop you from becoming pregnant. Therefore, it is important you use condoms until your next period.</p><p>If you wish to start or continue with a regular method of contraception after using this medicine, you can do so but you should also use condoms until your next period.</p><p><strong>Driving and using machines</strong></p><p>After taking this medicine, some women experience dizziness, drowsiness, blurred vision and/or loss of concentration (see section 4 &ldquo;Possible side effects&rdquo;). If you experience these symptoms, do not drive or use machines.</p><p><strong>Ecinq contains lactose&nbsp;</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p><strong>Ecinq contains sodium</strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>3.&nbsp; How to take Ecinq&nbsp;</strong></p><p>Always take this medicine exactly as described in this leaflet or as your pharmacist, doctor or other healthcare professional has told you. Check with your pharmacist or doctor if you are not sure.</p><p><u>How to take the Ecinq film-coated tablet</u></p><ul><li>Take one tablet by mouth as soon as possible and no later than 5 days (120 hours) after unprotected sexual intercourse or contraceptive failure. Take the tablet without delay.</li><li>You can take this medicine at any time in your cycle.</li><li>You can take this medicine at any time of the day either before, during or after a meal.</li><li>&nbsp;If you are using one of the medicines that may prevent Ecinq from working properly (see section above &ldquo;Other medicines and Ecinq&rdquo;) or if you have used one of these medicines in the past 4 weeks, Ecinq may work less effectively for you. Speak to your doctor or pharmacist before using ECINQ. Your doctor may prescribe another type of (non-hormonal) emergency contraceptive, i.e. a copper intrauterine device (Cu-IUD).</li></ul><p><u>If you vomit after taking Ecinq</u></p><p>If you vomit (be sick, throw up) within 3 hours of taking the tablet, take another tablet as soon as possible.</p><p><u>If you have sexual intercourse again after taking Ecinq</u></p><p>If you have unprotected sexual intercourse after taking the tablet, it will not stop you from becoming pregnant. After you take the tablet and until your next period comes, you should use condoms every time you have sexual intercourse.</p><p><u>If your next period is late after taking Ecinq</u></p><p>After taking the tablet, it is normal for your next period to be a few days late.</p><p>However, if your period is more than 7 days late; if it is unusually light or unusually heavy; or if you experience symptoms such as abdominal (stomach) pain, breast tenderness, vomiting or nausea, you</p><p>may be pregnant. You should do a pregnancy test right away. If you are pregnant, it is important that</p><p>you see your doctor. (See section &ldquo;Pregnancy, breast-feeding and fertility&rdquo;)</p><p><u>If you take more Ecinq than you should</u></p><p>There have been no reports of harmful effects from taking a higher dose than recommended of this medicine. However do ask your pharmacist, doctor or other healthcare professional for advice.</p><p>If you have any further questions on the use of this medicine, ask your pharmacist, doctor or other healthcare professional.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>4.&nbsp; Possible side effects</strong></p><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Some symptoms such as breast tenderness and abdominal (stomach) pain, throwing up (vomiting), feeling sick (nausea) are also possible signs of pregnancy. If you miss your period and experience such symptoms after taking Ecinq, you should do a pregnancy test (See section &ldquo;Pregnancy, breastfeeding and fertility&rdquo;).</p><p><u>Common side effects</u> (<em>may affect up to 1 in 10 people)</em></p><ul><li>&nbsp;nausea, abdominal (stomach) pain or discomfort, vomiting</li><li>painful periods, pelvic pain, breast tenderness</li><li>headache, dizziness, mood swings</li><li>muscle pain, back pain, tiredness</li></ul><p><u>Uncommon side effects</u> <em>(may affect up to 1 in 100 people)</em></p><ul><li>&nbsp;diarrhoea, heartburn, wind, dry mouth</li><li>&nbsp;unusual or irregular vaginal bleeding, heavy/prolonged periods premenstrual syndrome, vaginal irritation or discharge, lesser or greater sexual drive</li><li>hot flushes</li><li>appetite changes, emotional disorders, anxiety, agitation, trouble sleeping, sleepiness, migraine visual disturbances</li><li>&nbsp;influenza</li><li>&nbsp;acne, skin lesions, itching</li><li>fever, chills, malaise</li></ul><p><u>Rare side effects</u> <em>(may affect up to 1 in 1,000 people)</em></p><ul><li>&nbsp;genital pain or itching, pain during sexual intercourse, rupture of an ovarian cyst, unusually light period</li><li>&nbsp;loss of concentration, vertigo, shaking, disorientation, fainting</li><li>unusual sensation in eye, red eye, sensitivity to light</li><li>dry throat, disturbance in taste</li><li>hives (itchy rash), feeling thirsty</li></ul><p><u>Reporting of side effects</u></p><p>If you get any side effects, talk to your pharmacist, doctor or other healthcare professional. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>5.&nbsp; How to store Ecinq</strong></p><p>Do not store above 30&deg;C.</p><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is on the carton and on the blister after marked EXP. The expiry date refers to the last day of that month.</p><p>Store in the original package in order to protect from light.</p><p>Do not throw away any medicines via waste water. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Ecinq contains</strong></p><ul><li>The active substance is ulipristal acetate. One film-coated tablet contains 30 milligrams of ulipristal acetate.</li><li>The other ingredients are lactose monohydrate, pregelatinised starch, sodium starch glycolate type (A), magnesium stearate, hypromellose (E464), hydroxypropylcellulose (E463), stearic acid (E570), talc (E553b), titanium dioxide (E171), Purified water.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
What Ecinq looks like and contents of the pack

Ecinq is a white, round, biconvex film-coated tablet of 9.0 - 9.2 mm diameter embossed with “U30” on one side.

Ecinq is available in carton containing one transparent PVC/PVDC/aluminium blister of 1 tablet.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder and Manufacturer </strong></p><p><strong>Marketing Authorisation Holder</strong></p><p>Aspen Healthcare Malta Limited<br />89, Level 0<br />Triq is-Siggiewi<br />Is-Siggiewi SGW 2021<br />Malta</p><p><strong>Manufacturer</strong></p><p>Haupt Pharma M&uuml;nster GmbH</p><p>Schleebr&uuml;ggenkamp 15</p><p>48159 M&uuml;nster</p><p>Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in {February/2024}, version number {3}. 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>1. ما هو إيسينك وما هي دواعي استخدامه</strong></p><p dir="RTL"><u>إيسينك دواء لمنع الحمل في الحالات الطارئة</u></p><p dir="RTL">إيسينك دواء لمنع الحمل في الحالات الطارئة وذلك في غضون 120 ساعة (5 أيام) بعد الجماع بدون وسيلة حماية أو في حالة فشل وسيلة منع الحمل. إيسينك ليس مخصصا للاستخدام الروتيني كوسيلة لمنع الحمل. على سبيل المثال:</p><ul dir="rtl"><li>&nbsp; &nbsp;في حالة الجماع بدون وسيلة حماية،</li><li>&nbsp; &nbsp; &nbsp;في حال تمزق الواقي الخاص بك أو بشريكك، أو انزلق أو انخلع، أو نسيتِ استخدامه،</li><li>&nbsp; &nbsp; &nbsp; إن لم تتناولي حبة منع الحمل وفقاً للتوصيات.</li></ul><p dir="RTL">هذا لأن الحيوان المنوي قد يستمر في الحياة حتى 5 أيام في جسمك بعد الجماع.</p><p dir="RTL">هذا الدواء مناسب لأي سيدة بعمر الإنجاب، بما في ذلك المراهقات.&nbsp;</p><p dir="RTL">يمكنك تناول هذا القرص بأي وقت خلال الدورة الشهرية.</p><p dir="RTL"><u>إيسينك غير فعال إذا كنت حامل بالفعل</u></p><p dir="RTL">إذا تأخرت الدورة الشهرية، فهناك احتمال أنك قد تكونين حاملاً. عند تأخر الدورة أو عند ظهور أعراض الحمل (ثقل الثديين، غثيان الصباح)، يجب أن تستشيري الطبيب أو أي أخصائي رعاية صحية آخر قبل تناول هذا القرص.</p><p dir="RTL">إذا مارستِ االجماع بدون وسيلة حماية بعد تناول هذا القرص، فلن يمنع ذلك حدوث الحمل.</p><p dir="RTL">فممارسة الجماع بدون وسيلة حماية بأي وقت خلال دورتك قد تؤدي إلى حدوث الحمل.</p><p><u>إيسينك غير مخصص للاستخدام كدواء منع حمل منتظم</u></p><p dir="RTL">إن لم تكوني مداومة على استخدام وسيلة منع حمل منتظمة، تحدثي إلى طبيبك أو أخصائي الرعاية الصحية لاختيار وسيلة تناسبك.</p><p dir="RTL"><u>كيفية عمل إيسينك</u></p><p dir="RTL">يحتوي إيسينك على مادة <em>أسيتات أوليبريستال &nbsp;</em>التي تعمل بتعديل نشاط هرمون بروجستيرون الطبيعي الضروري لحدوث التبويض. نتيجة لذلك، يعمل هذا الدواء على تأخير التبويض. أدوية منع الحمل الطارئة ليست فعالة في جميع الحالات. فمن بين 100 سيدة تتناول هذا الدواء، يحدث الحمل مع 2 تقريباً منهن.</p><p dir="RTL">هذا الدواء مانع للحمل يستخدم لمنع حدوث الحمل من بدايته. إذا حدث الحمل بالفعل، فلن يقاطعه.</p><p dir="RTL"><u>لا تقي أدوية منع الحمل الطارئة من الإصابة بعدوى الأمراض المنقولة جنسيا.</u></p><p dir="RTL">فقط الواقي يمكنه حمايتك من الإصابة بعدوى الأمراض المنقولة جنسيا. لن يقيك هذا الدواء من الإصابة بعدوى فيروس العوز المناعي البشري (HIV) أو أي أمراض أخرى منقولة جنسياً (مثل المتدثرة، الهربس التناسلي، الثآليل التناسلية، السيلان، الإلتهاب الكبدي ب والزهري). أطلبي المشورة من أخصائي رعاية صحية إذا كنتِ قلقة من الإصابة بهذه الأمراض.</p><p dir="RTL">يوجد المزيد من المعلومات حول منع الحمل في نهاية هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>2. ما الذي تحتاجين لمعرفته قبل تناول إيسينك</strong></p><p dir="RTL"><strong>لا تتناولي إيسينك</strong></p><ul dir="rtl"><li>&nbsp;إذا كنت تعانين من الحساسية لمادة أسيتات أوليبريستال &nbsp;أو لأي من مكونات هذا الدواء (المذكورة في القسم 6).</li></ul><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدثي إلى الصيدلي، أو الطبيب أو أخصائي رعاية صحية آخر قبل تناول هذا الدواء:</p><ul dir="rtl"><li>&nbsp; تأخرت دورتك الشهرية أو ظهرت عليكِ أعراض الحمل (ثقل الثديين، غثيان الصباح)، حيث قد تكونين حاملاً بالفعل (راجعي قسم &quot;الحمل، والرضاعة الطبيعة والخصوبة<em> &quot;) </em><em>;</em></li><li>&nbsp; إذا كنتِ تعانين من أزمة ربو حادة،</li><li>&nbsp; &nbsp;إذا كنتِ تعانين من مرض كبدي حاد.</li></ul><p dir="RTL">أسيتات أوليبريستال 30 ملغ هو للإستخدام العرضي فقط. لا ينبغي أبدًا استخدامه بدلاً من وسيلة منع الحمل العادية. تم الإبلاغ عن حالات إصابة خطيرة في الكبد وفشل كبدي (تتطلب الزراعة في بعض الحالات) وذلك أثناء التعرض أسيتات أوليبريستال لفترات طويلة.</p><p dir="RTL">لجميع السيدات، يجب تناول دواء منع الحمل الطارئ بأقرب وقت ممكن بعد الجماع بدون وسيلة حماية. توجد بعض الأدلة التي تشير إلى احتمال انخفاض فعالية هذا الدواء مع ازدياد وزن الجسم أو مؤشر كتلة الجسم (BMI)، إلا أن هذه البيانات كانت محدودة وغير حاسمة. لذا، لا يزال يوصى باستخدام إيسينك لجميع السيدات بغض النظر عن أوزانهن أو مؤشر كتلة الجسم (BMI) لديهن.</p><p dir="RTL">يُنصح بالتحدث إلى أخصائي رعاية صحية إذا كنتِ قلقة من حدوث أي مشكلة متعلقة بتناول مانع الحمل الطارئ.</p><p dir="RTL">إذا أصبحتِ حاملاً رغم تناول هذا الدواء، فمن المهم أن تراجعي طبيبك. ارجعي إلى قسم &quot;الحمل، والرضاعة الطبيعية والخصوبة&quot; لمزيد من المعلومات</p><p dir="RTL"><strong>أدوية منع الحمل الأخرى و </strong><strong>إيسينك</strong></p><p dir="RTL">قد يتسبب هذا الدواء في تقليل فعالية أدوية منع الحمل الهرمونية المنتظمة، مثل الحبوب واللاصقات، بشكل مؤقت.</p><p dir="RTL">إذا كنتِ تتناولين في الوقت الحالي أدوية منع حمل هرمونية، واصلي استخدامها كالمعتاد بعد تناول القرص، لكن احرصي على استخدام الواقي بكل مرة تمارسين بها الجماع حتى نزول دورتك التالية.</p><p dir="RTL">لا تستخدمي إيسينك إلى جانب حبوب منع حمل طارئة أخرى تحتوي على هرمون ليفونورجيستريل، حيث أن تناولهما معاً قد يقلل فعالية هذا الدواء.</p><p dir="RTL"><strong>الأدوية الأخرى وإيسينك</strong></p><p dir="RTL">أخبري طبيبك أو الصيدلي أو أي أخصائي رعاية صحية آخر إذا كنتِ تتناولين أو تناولتي مؤخراً أي أدوية أخرى، وهذا يشمل الأدوية التي يمكن شراؤها دون وصفة طبية والأدوية العشبية.</p><p dir="RTL">فبعض الأدوية قد تحول دون عمل إيسينك بفعالية. إذا سبق لكِ استخدام أي من الأدوية المدرجة أدناه خلال الأسابيع الأربعة الماضية ، قد لا يكون إيسينك مناسباً تماماً لكِ. قد يصف لكِ طبيبك وسيلة منع حمل طارئة (غير هرمونية) من نوع آخر، على سبيل المثال لولب رحمي نحاسي (Cu-IUD):</p><ul dir="rtl"><li>الأدوية المستخدمة في علاج الصرع (على سبيل المثال، بريميدون، فينوباربيتال، فينيتوين، فوسفينيتوين، كربامازيبين، أوكسكاربازيبين وباربتيورات)</li><li>&nbsp;الأدوية المستخدمة في علاج السل (على سبيل المثال، ريفامبيسين، ريفابوتين)</li><li>علاج فيروس العوز المناعي البشري (HIV) (ريتونافير، ايفافيرنز، نيفيرابين)</li><li>دواء يستخدم في علاج العدوى الفطرية (غريسيوفلفين).</li><li>العلاجات العشبية التي تحتوي نبتة القديس يوحنا المثقبة <em>(هايبيريكم بيرفراتم)</em>.</li></ul><p dir="RTL">تحدثي إلى طبيبك أو الصيدلي قبل استخدام إيسينك إذا كنتِ تستخدمين (أو استخدمتِ مؤخراً) أي من الأدوية المدرجة أعلاه.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية والخصوبة</strong></p><p dir="RTL"><em><u>الحمل</u></em></p><p dir="RTL">قبل تناول هذا الدواء، إذا تأخرت دورتك الشهرية، أخبري الصيدلي، أو الطبيب أو أخصائي رعاية صحية آخر، أو قومي بإجراء اختبار الحمل للتأكد أنك لستِ حاملاً بالفعل (راجعي قسم&nbsp; <em>&quot;</em>التحذيرات والاحتياطات&quot;).</p><p dir="RTL">هذا الدواء مانع للحمل يستخدم لمنع بدء الحمل. إذا حدث الحمل بالفعل، فلن يقاطعه.</p><p dir="RTL">إذا أصبحتِ حاملاً رغم تناول إيسينك، فإننا نشجعك أن تطلبي من طبيبك أن يقيد حملك في سجل رسمي. مشاركة هذه المعلومات قد تساعد السيدات في المستقبل على فهم مدى أمان أو خطورة إيسينك خلال الحمل.</p><p dir="RTL"><em><u>الرضاعة الطبيعية</u></em></p><p dir="RTL">إذا تناولتِ هذه الدواء بوقت كنتِ ترضعين طفلاً رضاعة طبيعية، امتنعي عن الإرضاع لمدة أسبوع واحد بعد تناول إيسينك. خلال هذا الوقت، يوصى باستخدام مضخة الثدي لمواصلة إنتاج الحليب، لكن يجب عليكِ التخلص من حليب الثدي. تأثير إرضاع طفلك في الأسبوع التالي لتناول هذا الدواء غير معروف.</p><p dir="RTL"><em><u>الخصوبة</u></em></p><p dir="RTL">لن يؤثر هذا الدواء على خصوبتك في المستقبل. إذا مارستِ الجماع بدون وسيلة حماية بعد تناول هذا الدواء، فلن يمنع ذلك حدوث الحمل. لذا من الضروري أن تستخدمي الواقي حتى موعد دورتك الشهرية التالية.</p><p dir="RTL">إذا رغبتِ في بدء أو مواصلة استخدام وسيلة منع حمل منتظمة بعد استخدام هذا الدواء، يمكنك ذلك إلا إنه يجب عليكِ استخدام الواقي حتى موعد دورتك الشهرية التالية.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">بعد تناول هذا الدواء، تشعر بعض السيدات بدوّار، ودوخة، وتشوش الرؤية، و/أو فقدان التركيز (راجعي قسم 4 &quot;الآثار الجانبية المحتملة&quot;). إذا ظهرت عليكِ هذه الأعراض، يجب عليكِ الامتناع عن القيادة أو استخدام الآلات.</p><p dir="RTL"><strong>يحتوي إيسينك على اللاكتوز.</strong></p><p dir="RTL">إذا أخبركِ طبيبك أنكِ مصابة بعدم القدرة على تحمل بعض أنواع السكر، اتصلي بطبيبك قبل تناول هذا الدواء.</p><p dir="RTL"><strong>يحتوي إيسينك على الصوديوم.</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول من الصوديوم (23 ملغ) في كل قرص، أي أنه في الأساس &quot;خال من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>3. كيفية تناول إيسينك</strong></p><p dir="RTL">تناولي هذا الدواء دائماً بالطريقة الموصوفة في هذه النشرة أو وفقاً لتعليمات الصيدلي، أو الطبيب أو أي أخصائي رعاية صحية آخر. استشيري الصيدلي أو طبيبك إذا لم تكوني متأكدة.</p><p dir="RTL"><u>كيفية تناول أقراص إيسينك المغلفة</u></p><ul dir="rtl"><li>&nbsp; &nbsp;تناولي قرصاً واحداً عن طريق الفم في أقرب وقت ممكن لا يتجاوز 5 أيام (120 ساعة) بعد ممارسة الجماع بدون وسيلة حماية أو إخفاق وسيلة منع الحمل. خذي القرص بدون تأخير.</li><li>&nbsp; &nbsp;يمكنك تناول هذا الدواء في أي وقت خلال فترة الدورة الشهرية.</li><li>&nbsp; &nbsp;يمكنك تناول هذا الدواء بأي وقت من اليوم إما أثناء تناول الوجبات أو قبلها أو بعدها.</li><li>&nbsp; &nbsp; إذا كنتِ تستخدمين إحدى الأدوية التي قد تحول دون عمل إيسينك بفعالية (راجعي القسم أعلاه &quot;الأدوية الأخرى وإيسينك&quot;) أو استخدمتِ إحدى هذه الأدوية خلال الأسابيع الـ 4 الماضية، قد تنخفض فعالية إيسينك. تحدثي إلى طبيبك أو الصيدلي قبل استخدام إيسينك. قد يصف لكِ طبيبك وسيلة منع حمل طارئة (غير هرمونية) من نوع آخر، على سبيل المثال لولب رحمي نحاسي (Cu-IUD).</li></ul><p dir="RTL"><u>في حالة القيء بعد تناول إيسينك</u></p><p dir="RTL">إذا تقيأتي خلال 3 ساعات من تناول القرص، تناولي قرصاً آخراً بأقرب وقت ممكن.</p><p dir="RTL"><u>في حالة الجماع مرة أخرى بعد تناول إيسينك</u></p><p dir="RTL">إذا مارستي الجماع بدون وسيلة حماية بعد تناول هذا القرص، فلن يمنع ذلك حدوث الحمل. بعد تناول القرص وحتى موعد دورتك الشهرية التالية، يجب عليكِ استخدام الواقي في كل مرة تمارسين فيها الجماع.</p><p dir="RTL"><u>في حالة تأخر الدورة التالية بعد تناول إيسينك </u></p><p dir="RTL">بعد تناول القرص، من الطبيعي أن تتأخر دورتك التالية لبضعة أيام.</p><p dir="RTL">إلا إنه إذا تأخرت دورتك الشهرية لأكثر من 7 أيام، أو كانت خفيفة أو غزيرة على غير المعتاد، أو ظهرت عليكِ أعراض مثل ألم بالبطن (المعدة)، أو طراوة الثديين، أو قيء أو غثيان، قد تكونين حاملاً. يجب عليكِ إجراء اختبار الحمل على الفور. إذا كنتِ حاملاً، فمن الضروري أن تري طبيبك. (راجعي قسم &quot;الحمل، والرضاعة الطبيعية والخصوبة&quot;)</p><p dir="RTL"><u>في حالة تناول جرعة أكبر من اللازم من إيسينك</u></p><p dir="RTL">لم ترد أي بلاغات عن حدوث آثار ضارة من تناول جرعة أكبر من الموصى بها من هذا الدواء، لكن اطلبي المشورة من الصيدلي، أو الطبيب أو أخصائي رعاية صحية آخر.</p><p dir="RTL">إن كان لديكِ أي استفسارات أخرى حول استخدام هذا الدواء، فاسألي الصيدلي، أو الطبيب أو أخصائي رعاية صحية آخر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p><strong>4. الآثار الجانبية المحتملة</strong></p><p dir="RTL">مثل جميع الأدوية يمكن لهذا الدواء أن يسبب آثاراً جانبية، على الرغم من أنه ليس بالضرورة أن يعاني منها الجميع.</p><p dir="RTL">بعض الأعراض مثل طراوة الثديين وألم البطن (المعدة)، والقيء، والرغبة في القيء (الغثيان) تعد أيضاً علامات محتملة للحمل. إذا تأخر نزول دورتك الشهرية وظهرت عليك هذه الأعراض بعد تناول إيسينك، يجب عليكِ إجراء اختبار الحمل (راجعي قسم &quot;الحمل، والرضاعة الطبيعية والخصوبة&quot;).</p><p dir="RTL"><u>آثار جانبية شائعة</u> <em>&nbsp;(قد تؤثر على </em><em>1</em><em> من كل </em><em>10</em><em> أشخاص)</em></p><ul dir="rtl"><li>&nbsp;غثيان، عدم ارتياح أو ألم بالبطن (المعدة)، قيء</li><li>&nbsp;دورات شهرية مصحوبة بألم، ألم بالحوض، طراوة الثديين</li><li>&nbsp;صداع، دوّار، تقلبات مزاجية</li><li>&nbsp;ألم عضلي، ألم بالظهر، إجهاد</li></ul><p dir="RTL"><u>آثار جانبية غير شائعة</u> <em>&nbsp;(قد تؤثر على </em><em>1</em><em> من كل </em><em>100</em><em> شخص)</em></p><ul dir="rtl"><li>&nbsp;إسهال، حرقة في المعدة، ريح البطن، جفاف الفم</li><li>&nbsp;نزيف مهبلي غير معتاد أو غير منتظم، دورات شهرية غزيرة أو مطولة، متلازمة ما قبل الطمث، تهيجات أو إفرازات &nbsp;مهبلية، انخفاض أو ازدياد الرغبة في الجماع</li><li>&nbsp;هبات ساخنة</li><li>&nbsp;تغير الشهية، اضطرابات عاطفية، قلق، هياج، صعوبة النوم، نعاس، صداع نصفي اضطرابات بصرية</li><li>&nbsp;إنفلونزا</li><li>بثور، آفات جلدية، حكة</li><li>&nbsp;حمى، رعشة، توعك</li></ul><p dir="RTL"><u>آثار جانبية نادرة</u> <em>&nbsp;(قد تؤثر على </em><em>1</em><em> من كل </em><em>1000</em><em> شخص)</em></p><ul dir="rtl"><li>&nbsp;حكة أو ألم بالأعضاء التناسلية، ألم أثناء الجماع، تمزق الكيسة المبيضية، دورة شهرية خفيفة على غير المعتاد</li><li>&nbsp;فقدان التركيز، دوّار، ارتجاف، توهان، إغماء</li><li>&nbsp;إحساس غير معتاد بالعين، إحمرار العين، حساسية من الضوء</li><li>جفاف الحلق، اضطراب التذوق</li><li>&nbsp;شرى (طفح جلدي مصحوب بحكة)، شعور بالعطش</li></ul><p dir="RTL"><u>الإبلاغ عن الآثار الجانبية:</u></p><p dir="RTL">إذا ظهرت عليكِ أي أعراض جانبية، فتحدثي إلى الصيدلي أو الطبيب أو أي أخصائي رعاية صحية آخر. وذلك يتضمن أي أعراض جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنكِ المساعدة في تقديم المزيد من المعلومات حول مدى أمان هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>5</strong><strong>. كيفية تخزين إيسينك</strong></p><p dir="RTL">لا يحفظ في درجة حرارة أعلى من 30 درجة مئوية.</p><p dir="RTL">يُحفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا تستخدمي هذا الدواء بعد تاريخ انتهاء الصلاحية الموضح على العلبة الكرتونية وعلى الشريط بعد عبارة &quot;تاريخ انتهاء الصلاحية&quot; (EXP). يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p dir="RTL">يحفظ في العبوة الأصلية لحمايته من الضوء.</p><p dir="RTL">لا تتخلصي من أي أدوية في ماء الصرف الصحي. اسألي الصيدلي عن كيفية التخلص من الأدوية التي لم تعودي بحاجة إليها. ستساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات إيسينك</strong></p><ul dir="rtl"><li>&nbsp;المادة الفعالة هي أسيتات أوليبريستال . قرص مغلف واحد يحتوي 30 ملغ من أسيتات الأوليبريستال.</li><li>المكونات الأخرى هي لاكتوز أحادي الهيدرات، نشاء مسبق التجلتن (ذرة)، غليكولات نشا الصوديوم النوع (أي)، ستيارات المغنيسيوم، هيبروميلوز (إي 464)، هيدروكسي بروبيل السليولوز (إي 463)، حمض الستياريك (إي 570)، تلك (إي 553 بي)، ثاني أكسيد التيتانيوم (إي 171)، ماء منقى.</li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp;</strong></p><p dir="RTL">إيسينك قرص مغلف أبيض مستدير محدب من الجانبين، قطره من 9.0 - 9.2 مم، محفور على إحدى جانبيه &quot;U30&quot;.</p><p dir="RTL">إيسينك متوفر في علبة كرتونية تحتوي شريطاً واحداً من بولي فينيل كلورايد/بولي فينيلدين كلوريد/ ألومونيوم يحتوي على قرص واحد.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التسويق والمُصَّنع</strong></p><p dir="RTL"><strong>مالك حق التسويق</strong></p><p dir="RTL">أسبن هيلثكير مالطا المحدودة</p><p dir="RTL">89 ، الطابق 0</p><p dir="RTL">شارع سيغيوي</p><p dir="RTL">سيغيوي ، SGW 2021</p><p dir="RTL">مالطا</p><p dir="RTL"><strong>المُصَّنع:</strong></p><p dir="RTL">هوبت فارما مونسترجي أم بي أتش</p><p dir="RTL">شليبروجينكامب 15</p><p dir="RTL">48159 &nbsp;مونستر</p><p dir="RTL">ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في{ فبراير /2024 }، رقم النسخة {3}.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ecinq 30 mg film coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 30 mg ulipristal acetate. 
Excipients with known effect:
Each tablet contains 240.0 mg of lactose (as monohydrate) and 1.35 mg sodium. 
For the full list of excipients, see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet
White, round, biconvex, film-coated tablet of 9.0 – 9.2 mm diameter embossed with “U30” on one side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Emergency contraception within 120 hours (5 days) of unprotected sexual intercourse or contraceptive failure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Ecinq is indicated for emergency contraception within 120 hours (5 days) of unprotected sexual intercourse or contraceptive failure. Ecinq is not intended for routine use as a contraceptive.</p><p>This tablet can be taken at any time during the menstrual cycle.</p><p>If vomiting occurs within 3 hours of the tablet intake, another tablet should be taken.</p><p>If a woman&rsquo;s menstrual period is late or in case of symptoms of pregnancy, pregnancy should be excluded before the tablet is administered.</p><p><u>Special populations</u></p><p><em>Renal impairment</em></p><p>No dose adjustment is necessary.</p><p><em>Hepatic impairment</em></p><p>In the absence of specific studies, no alternate dose recommendations for Ecinq can be made.</p><p><em>Severe hepatic impairment</em></p><p>In the absence of specific studies, Ecinq is not recommended.</p><p><em>Paediatric population</em></p><p>There is no relevant use of ulipristal acetate for children of prepubertal age in the indication emergency contraception<em>.</em></p><p>Adolescents: ulipristal acetate is suitable for any woman of child bearing age, including adolescents. No differences in safety or efficacy have been shown compared to adult women aged 18 and older (see section 5.1).</p><p><u>Method of administration</u></p><p>Oral use.</p><p>The tablet can be taken with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ulipristal acetate 30 mg is for occasional use only. It should never be used in place of a regular contraceptive method. Cases of serious liver injury and liver failure (requiring transplantation in some cases) have been reported with prolonged exposure to Ulipristal Acetate.</p><p>Ulipristal acetate is not intended for use during pregnancy and should not be taken by any woman suspected or known to be pregnant. However, it does not interrupt an existing pregnancy (see section 4.6).</p><p>Ulipristal acetate<u> does not prevent pregnancy in every case.</u></p><p>In case the next menstrual period is more than 7 days late, if the menstrual period is abnormal in character or if there are symptoms suggestive of pregnancy or in case of doubt, a pregnancy test should be performed. As with any pregnancy, the possibility of an ectopic pregnancy should be considered. It is important to know that the occurrence of uterine bleeding does not rule out ectopic pregnancy. Women who become pregnant after taking ulipristal acetate should contact their doctor (see section 4.6).</p><p>Ulipristal acetate inhibits or postpones ovulation (see section 5.1). If ovulation has already occurred, it is no longer effective. The timing of ovulation cannot be predicted and therefore the tablet should be taken as soon as possible after unprotected intercourse.</p><p>No data are available on the efficacy of ulipristal acetate when taken more than 120 hours (5 days) after unprotected intercourse.</p><p>Limited and inconclusive data suggest that there may be reduced efficacy of ulipristal acetate with increasing body weight or body mass index (BMI) (see section 5.1). In all women, emergency contraception should be taken as soon as possible after unprotected intercourse, regardless of the woman&rsquo;s body weight or BMI.</p><p>After the tablet intake menstrual periods can sometimes occur a few days earlier or later than expected. In approximately 7% of the women, menstrual periods occurred more than 7 days earlier than expected. In 18.5% of the women a delay of more than 7 days occurred, and in 4% the delay was greater than 20 days.</p><p>Concomitant use of ulipristal acetate and emergency contraception containing levonorgestrel is not recommended (see section 4.5).</p><p><u>Contraception after ulipristal acetate intake</u></p><p>Ulipristal acetate is an emergency contraceptive that decreases pregnancy risk after unprotected intercourse but does not confer contraceptive protection for subsequent acts of intercourse.</p><p>Therefore, after using emergency contraception, women should be advised to use a reliable barrier method until her next menstrual period.</p><p>Although the use of ulipristal acetate does not contraindicate the continued use of regular hormonal contraception, ulipristal acetate may reduce its contraceptive action (see section 4.5). Therefore, if a woman wishes to start or continue using hormonal contraception, she can do so after using ulipristal acetate, however, she should be advised to use a reliable barrier method until the next menstrual period.</p><p><u>Specific populations</u></p><p>Concomitant use of ulipristal acetate with CYP3A4 inducers is not recommended due to interaction (e.g. barbiturates (including primidone and phenobarbital), phenytoin, fosphenytoin, carbamazepine, oxcarbazepine, herbal medicinal products containing <em>Hypericum perforatum </em>(St. John&rsquo;s wort), rifampicin, rifabutin, griseofulvin, efavirenz, nevirapine and long-term use of ritonavir).</p><p>Use in women with severe asthma treated by oral glucocorticoid is not recommended<strong>. </strong></p><p><u>Excipients</u></p><p>This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Potential for other medicinal products to affect ulipristal acetate</u></p><p>Ulipristal acetate is metabolized by CYP3A4 <em>in vitro</em>.</p><p>-&nbsp;<em>CYP3A4 inducers</em></p><p><em>In vivo </em>results show that the administration of ulipristal acetate with a strong CYP3A4 inducer such as rifampicin markedly decreases Cmax and AUC of ulipristal acetate by 90% or more and decreases ulipristal acetate half-life by 2.2-fold corresponding to an approximately 10-fold decrease of ulipristal acetate exposure. Concomitant use of Ecinq with CYP3A4 inducers (e.g. barbiturates (including primidone and phenobarbital), phenytoin, fosphenytoin, carbamazepine, oxcarbazepine, herbal medicinal products containing <em>Hypericum perforatum </em>(St. John&rsquo;s wort), rifampicin, rifabutin, griseofulvin, efavirenz and nevirapine) therefore reduces plasma concentrations of ulipristal acetate and may result in a decreased efficacy of Ecinq.</p><p>For women who have used enzyme-inducing drugs in the past 4 weeks, Ecinq is not recommended (see section 4.4) and non-hormonal emergency contraception (i.e. a copper intrauterine device (Cu-IUD)) should be considered.</p><p>-&nbsp;<em>CYP3A4 inhibitors</em></p><p><em>In vivo </em>results show that administration of ulipristal acetate with a potent and a moderate CYP3A4 inhibitor increased Cmax and AUC of ulipristal acetate with a maximum of 2- and 5.9-fold, respectively. The effects of CYP3A4 inhibitors are unlikely to have any clinical consequences.</p><p>The CYP3A4 inhibitor ritonavir can also have an inducing effect on CYP3A4 when ritonavir is used for a longer period. In such cases ritonavir might reduce plasma concentrations of ulipristal acetate. Concomitant use is therefore not recommended (see section 4.4). Enzyme induction wears off slowly and effects on the plasma concentrations of ulipristal acetate may occur even if a woman has stopped taking an enzyme inducer in the past 4 weeks.</p><p><em>Medicinal products affecting gastric pH</em></p><p>Administration of ulipristal acetate (10 mg tablet) together with the proton pump inhibitor esomeprazole (20 mg daily for 6 days) resulted in approximately 65% lower mean Cmax, a delayed Tmax (from a median of 0.75 hours to 1.0 hours) and 13% higher mean AUC. The clinical relevance of this interaction for single dose administration of ulipristal acetate as emergency contraception is not known.</p><p><u>Potential for ulipristal acetate to affect other medicinal products</u></p><p><em>Hormonal contraceptives</em></p><p>Because ulipristal acetate binds to the progesterone receptor with high affinity, it may interfere with the action of progestogen-containing medicinal products:</p><p>- Contraceptive action of combined hormonal contraceptives and progestogen-only contraception may be reduced</p><p>- Concomitant use of ulipristal acetate and emergency contraception containing levonorgestrel is not recommended (see section 4.4).</p><p><em>In vitro </em>data indicate that ulipristal acetate and its active metabolite do not significantly inhibit CYP1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4, at clinically relevant concentrations. After single dose administration induction of CYP1A2 and CYP3A4 by ulipristal acetate or its active metabolite is not likely. Thus, administration of ulipristal acetate is unlikely to alter the clearance of medicinal products that are metabolised by these enzymes.</p><p><em>P-glycoprotein (P-gp) substrates</em></p><p><em>In vitro </em>data indicate that ulipristal acetate may be an inhibitor of P-gp at clinically relevant concentrations. Results <em>in vivo </em>with the P-gp substrate fexofenadine were inconclusive. The effects of the P-gp substrates are unlikely to have any clinical consequences.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Ecinq is not intended for use during pregnancy and should not be taken by any woman suspected or known to be pregnant (see section 4.2).</p><p>Ulipristal acetate does not interrupt an existing pregnancy.</p><p>Pregnancy may occasionally occur after Ecinq intake. Although no teratogenic potential has been observed, animal data are insufficient with regard to reproduction toxicity (see section 5.3). Limited human data regarding pregnancy exposure to ulipristal acetate do not suggest any safety concern.</p><p>Nevertheless, it is important that any pregnancy in a woman who has taken Ecinq be reported to Aspen Healthcare Malta Limited. The purpose of this web-based registry is to collect safety information from women who have taken Ecinq during pregnancy or who become pregnant after Ecinq intake. All patient data collected will remain anonymous.</p><p><u>Breast-feeding</u></p><p>Ulipristal acetate is excreted in breast milk (see section 5.2). The effect on newborn/infants has not been studied. A risk to the breastfed child cannot be excluded. After intake of Ecinq, breastfeeding is not recommended for one week. During this time it is recommended to express and discard the breast milk in order to stimulate lactation.</p><p><u>Fertility</u></p><p>A rapid return of fertility is likely following treatment with Ecinq for emergency contraception. Women should be advised to use a reliable barrier method for all subsequent acts of intercourse until the next menstrual period.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ulipristal acetate may have minor or moderate influence on the ability to drive or use machines: mild to moderate dizziness is common after Ecinq intake, somnolence and blurred vision are uncommon; disturbance in attention has been rarely reported. The patient should be informed not to drive or use machines if they are experiencing such symptoms (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most commonly reported adverse reactions were headache, nausea, abdominal pain and dysmenorrhea.</p><p>Safety of ulipristal acetate has been evaluated in 4,718 women during the clinical development program.</p><p><u>Tabulated list of adverse reactions</u></p><p>The adverse reactions reported in the phase III program of 2,637 women are provided in the table below.</p><p>Adverse reactions listed below are classified according to frequency and system organ class using the following convention: very common (&ge;1/10), common (&ge; 1/100 to &lt;1/10), uncommon (&ge; 1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000) and not known (cannot be estimated from the available data)</p><table border="1" cellspacing="0" cellpadding="0" style="width:1037px"><tbody><tr><td style="vertical-align:top; width:215px"><p>MedDRA</p></td><td colspan="3" style="vertical-align:top; width:820px"><p>Adverse reactions (frequency)</p></td></tr><tr><td style="vertical-align:top; width:215px"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top; width:196px"><p><strong>Common</strong></p></td><td style="vertical-align:top; width:362px"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top; width:262px"><p><strong>Rare</strong></p></td></tr><tr><td style="vertical-align:top; width:215px"><p>Infections and infestations</p></td><td style="vertical-align:top; width:196px"><p>&nbsp;</p></td><td style="vertical-align:top; width:362px"><p>Influenza</p></td><td style="vertical-align:top; width:262px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:215px"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top; width:196px"><p>&nbsp;</p></td><td style="vertical-align:top; width:362px"><p>Appetite disorders</p></td><td style="vertical-align:top; width:262px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:215px"><p>Psychiatric disorders</p></td><td style="vertical-align:top; width:196px"><p>Mood disorders</p></td><td style="vertical-align:top; width:362px"><p>Emotional disorder Anxiety</p><p>Insomnia Hyperactivity disorder</p><p>Libido changes</p></td><td style="vertical-align:top; width:262px"><p>Disorientation</p></td></tr><tr><td style="vertical-align:top; width:215px"><p>Nervous system disorders</p></td><td style="vertical-align:top; width:196px"><p>Headache Dizziness</p></td><td style="vertical-align:top; width:362px"><p>Somnolence Migraine</p></td><td style="vertical-align:top; width:262px"><p>Tremor Disturbance in attention Dysgueusia</p><p>Syncope</p></td></tr><tr><td style="vertical-align:top; width:215px"><p>Eye disorders</p></td><td style="vertical-align:top; width:196px"><p>&nbsp;</p></td><td style="vertical-align:top; width:362px"><p>Visual disturbance</p></td><td style="vertical-align:top; width:262px"><p>Abnormal sensation in eye</p><p>Ocular hyperaemia Photophobia</p></td></tr><tr><td style="vertical-align:top; width:215px"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top; width:196px"><p>&nbsp;</p></td><td style="vertical-align:top; width:362px"><p>&nbsp;</p></td><td style="vertical-align:top; width:262px"><p>Vertigo</p></td></tr><tr><td style="vertical-align:top; width:215px"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top; width:196px"><p>&nbsp;</p></td><td style="vertical-align:top; width:362px"><p>&nbsp;</p></td><td style="vertical-align:top; width:262px"><p>Dry throat</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top; width:196px"><p>Nausea* Abdominal pain* Abdominal</p><p>discomfort Vomiting*</p></td><td style="vertical-align:top; width:363px"><p>Diarrhoea Dry mouth Dyspepsia Flatulence</p></td><td style="vertical-align:top; width:256px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top; width:196px"><p>&nbsp;</p></td><td style="vertical-align:top; width:363px"><p>Acne</p><p>Skin lesion Pruritus</p></td><td style="vertical-align:top; width:256px"><p>Urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and</p><p>connective tissue disorders</p></td><td style="vertical-align:top; width:196px"><p>Myalgia Back pain</p></td><td style="vertical-align:top; width:363px"><p>&nbsp;</p></td><td style="vertical-align:top; width:256px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top; width:196px"><p>Dysmenorrhea Pelvic pain Breast tenderness</p></td><td style="vertical-align:top; width:363px"><p>Menorrhagia Vaginal discharge Menstrual disorder Metrorrhagia Vaginitis</p><p>Hot flush Premenstrual syndrome</p></td><td style="vertical-align:top; width:256px"><p>Genital pruritus Dyspareunia Ruptured ovarian cyst</p><p>Vulvovaginal pain Hypomenorrhea*</p></td></tr><tr><td style="vertical-align:top"><p>General disorders</p><p>and administration site conditions</p></td><td style="vertical-align:top; width:196px"><p>Fatigue</p></td><td style="vertical-align:top; width:363px"><p>Chills</p><p>Malaise Pyrexia</p></td><td style="vertical-align:top; width:256px"><p>Thirst</p></td></tr></tbody></table><p>*Symptom which could also be related to an undiagnosed pregnancy (or related complications)</p><p>Adolescents: the safety profile observed in women less than 18 years old in studies and post- marketing is similar to the safety profile in adults during the phase III program (Section 4.2).</p><p>Post-marketing experience: the adverse reactions spontaneously reported in post-marketing experience were similar in nature and frequency to the safety profile described during the phase III program.</p><p><u>Description of selected adverse reactions</u></p><p>The majority of women (74.6%) in the phase III studies had their next menstrual period at the expected time or within &plusmn; 7 days, while 6.8% experienced menses more than 7 days earlier than expected and 18.5% had a delay of more than 7 days beyond the anticipated onset of menses. The delay was greater than 20 days in 4 % of the women.</p><p>A minority (8.7%) of women reported intermenstrual bleeding lasting an average of 2.4 days. In a majority of cases (88.2%), this bleeding was reported as spotting. Among the women who received ulipristal acetate in the phase III studies, only 0.4% reported heavy intermenstrual bleeding.</p><p>In the phase III studies, 82 women entered a study more than once and therefore received more than one dose of ulipristal acetate (73 women enrolled twice and 9 enrolled three times). There were no safety differences in these subjects in terms of incidence and severity of adverse events, change in duration or volume of menses or incidence of intermenstrual bleeding.</p><p><u>To reports any side effect(s):</u></p><p><strong>Saudi Arabia:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>The National Pharmacovigilance Centre (NPC):</p><ul><li>SFDA Call Center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: <u>https://ade.sfda.gov.sa/</u></li></ul></td></tr></tbody></table><p><strong>Other GCC States:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>- Please contact the relevant competent authority.</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Experience with ulipristal acetate overdose is limited. Single doses up to 200 mg have been used in women without safety concern. Such high doses were well-tolerated; however, these women had a shortened menstrual cycle (uterine bleeding occurring 2-3 days earlier than would be expected) and in some women, the duration of bleeding was prolonged, although not excessive in amount (spotting).</p><p>There are no antidotes and further treatment should be symptomatic.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Sex hormones and modulators of the genital system, emergency contraceptives. ATC code: G03AD02.</p><p>Ulipristal acetate is an orally-active synthetic selective progesterone receptor modulator which acts via high-affinity binding to the human progesterone receptor. When used for emergency contraception the mechanism of action is inhibition or delay of ovulation via suppression of the luteinizing hormone (LH) surge. Pharmacodynamic data show that even when taken immediately before ovulation is scheduled to occur (when LH has already started to rise), ulipristal acetate is able to postpone follicular rupture for at least 5 days in 78.6% of cases (p&lt;0.005 vs. levonorgestrel and vs. placebo) (see Table).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p style="text-align:center">Prevention of ovulation<sup>1,&sect;</sup></p></td></tr><tr><td style="vertical-align:top"><p style="text-align:center">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:center"><strong>Placebo</strong></p><p style="text-align:center">n=50</p></td><td style="vertical-align:top"><p style="text-align:center"><strong>Levonorgestrel</strong></p><p style="text-align:center">n=48</p></td><td style="vertical-align:top"><p style="text-align:center"><strong>Ulipristal acetate</strong></p><p style="text-align:center">n=34</p></td></tr><tr><td style="vertical-align:top"><p><strong>Treatment before LH surge</strong></p></td><td style="vertical-align:top"><p style="text-align:center">n=16</p><p style="text-align:center">0.0%</p></td><td style="vertical-align:top"><p style="text-align:center">n=12</p><p style="text-align:center">25.0%</p></td><td style="vertical-align:top"><p style="text-align:center">n=8</p><p style="text-align:center">100%</p><p style="text-align:center">p&lt;0.005*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Treatment after LH surge but before LH peak</strong></p></td><td style="vertical-align:top"><p style="text-align:center">n=10</p><p style="text-align:center">10.0%</p></td><td style="vertical-align:top"><p style="text-align:center">n=14</p><p style="text-align:center">14.3%</p><p style="text-align:center">NS&dagger;</p></td><td style="vertical-align:top"><p style="text-align:center">n=14</p><p style="text-align:center">78.6%</p><p style="text-align:center">p&lt;0.005*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Treatment after LH peak</strong></p></td><td style="vertical-align:top"><p style="text-align:center">n=24</p><p style="text-align:center">4.2%</p></td><td style="vertical-align:top"><p style="text-align:center">n=22</p><p style="text-align:center">9.1%</p><p style="text-align:center">NS&dagger;</p></td><td style="vertical-align:top"><p style="text-align:center">n=12</p><p style="text-align:center">8.3%</p><p style="text-align:center">NS*</p></td></tr></tbody></table><p>1: Brache et al, Contraception 2013</p><p>&sect;: defined as presence of unruptured dominant follicle five days after late follicular-phase treatment</p><p>*: compared to levonorgestrel NS: non statistically significant</p><p>&dagger;: compared to placebo</p><p>Ulipristal acetate also has high affinity for the glucocorticoid receptor and <em>in vivo</em>, in animals, antiglucocorticoid effects have been observed. However, in humans, no such effect has been observed even after repeat administration at the daily dose of 10 mg. It has minimal affinity to the androgen receptor and no affinity for the human estrogen or mineralocorticoid receptors.</p><p>Results from two independent randomized controlled trials (see Table) showed the efficacy of ulipristal acetate to be non-inferior to that of levonorgestrel in women who presented for emergency contraception between 0 and 72 hours after unprotected intercourse or contraceptive failure. When the data from the two trials were combined via meta- analysis, the risk of pregnancy with ulipristal acetate was significantly reduced compared to levonorgestrel (p=0.046).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p style="text-align:center">Randomized controlled trial</p></td><td colspan="2" style="vertical-align:top"><p style="text-align:center">Pregnancy rate (%)</p><p style="text-align:center">within 72h of unprotected intercourse or contraceptive</p><p style="text-align:center">failure2</p></td><td rowspan="2" style="vertical-align:top"><p style="text-align:center">Odds ratio [95% CI] of pregnancy</p><p style="text-align:center">risk, ulipristal acetate vs levonorgestrel<sup>2</sup></p></td></tr><tr><td style="vertical-align:top"><p style="text-align:center">Ulipristal acetate</p></td><td style="vertical-align:top"><p style="text-align:center">Levonorgestrel</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:center">HRA2914-507</p></td><td style="vertical-align:top"><p style="text-align:center">0.91</p></td><td style="vertical-align:top"><p style="text-align:center">1.68</p></td><td style="vertical-align:top"><p style="text-align:center">0.50 [0.18-1.24]</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:center">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:center">(7/773)</p></td><td style="vertical-align:top"><p style="text-align:center">(13/773)</p></td><td style="vertical-align:top"><p style="text-align:center">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:center">HRA2914-513</p></td><td style="vertical-align:top"><p style="text-align:center">1.78</p></td><td style="vertical-align:top"><p style="text-align:center">2.59</p></td><td style="vertical-align:top"><p style="text-align:center">0.68 [0.35-1.31]</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:center">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:center">(15/844)</p></td><td style="vertical-align:top"><p style="text-align:center">(22/852)</p></td><td style="vertical-align:top"><p style="text-align:center">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:center">Meta- analysis</p></td><td style="vertical-align:top"><p style="text-align:center">1.36</p></td><td style="vertical-align:top"><p style="text-align:center">2.15</p></td><td style="vertical-align:top"><p style="text-align:center">0.58 [0.33-0.99]</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:center">&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:center">(22/1617)</p></td><td style="vertical-align:top"><p style="text-align:center">( 35/1625)</p></td><td style="vertical-align:top"><p style="text-align:center">&nbsp;</p></td></tr></tbody></table><p>2: Glasier et al, Lancet 2010</p><p>Two trials provide efficacy data on ulipristal acetate used up to 120 hours after unprotected intercourse. In an open-label clinical trial, which enrolled women who presented for emergency contraception and were treated with ulipristal acetate between 48 and 120 hours after unprotected intercourse, a pregnancy rate of 2.1% (26/1241) was observed. In addition, the second comparative trial described above also provides data on 100 women treated with ulipristal acetate from 72 to 120 hours after unprotected intercourse, in whom no pregnancies were observed.</p><p>Limited and inconclusive data from clinical trials suggest a possible trend for a reduced contraceptive efficacy of ulipristal acetate with high body weight or BMI (see section 4.4). Themeta-analysis of the four clinical studies conducted with ulipristral acetate presented below excluded women who had further acts of unprotected intercourse.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>BMI (kg/m<sup>2</sup>)</strong></p></td><td style="vertical-align:top"><p><strong>Underweight</strong><strong> </strong></p><p><strong>0 - 18.5</strong></p></td><td style="vertical-align:top"><p><strong>Normal</strong></p><p><strong>18.5-25</strong></p></td><td style="vertical-align:top"><p><strong>Overweight</strong><strong> </strong></p><p><strong>25-30</strong></p></td><td style="vertical-align:top"><p><strong>Obese</strong><strong> </strong></p><p><strong>30-</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>N total</strong></p></td><td style="vertical-align:top"><p>128</p></td><td style="vertical-align:top"><p>1866</p></td><td style="vertical-align:top"><p>699</p></td><td style="vertical-align:top"><p>467</p></td></tr><tr><td style="vertical-align:top"><p><strong>N pregnancies</strong></p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p><strong>Pregnancy rate</strong></p></td><td style="vertical-align:top"><p>0.00%</p></td><td style="vertical-align:top"><p>1.23%</p></td><td style="vertical-align:top"><p>1.29%</p></td><td style="vertical-align:top"><p>2.57%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Confidence</strong><strong> </strong><strong>Interval</strong></p></td><td style="vertical-align:top"><p>0.00 &ndash; 2.84</p></td><td style="vertical-align:top"><p>0.78 &ndash; 1.84</p></td><td style="vertical-align:top"><p>0.59 &ndash; 2.43</p></td><td style="vertical-align:top"><p>1.34 &ndash; 4.45</p></td></tr></tbody></table><p>A post-marketing observational study evaluating efficacy and safety of ulipristal acetate in adolescents aged 17 and younger showed no difference in the safety and efficacy profile compared to adult women aged 18 and older.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Following oral administration of a single 30 mg dose, ulipristal acetate is rapidly absorbed, with a peak plasma concentration of 176 &plusmn; 89 ng/ml occurring approximately 1 hour (0.5-2.0 h) after ingestion, and with an AUC0-&infin; of 556 &plusmn; 260 ng.h/ml.</p><p>Administration of ulipristal acetate together with a high-fat breakfast resulted in approximately 45% lower mean Cmax, a delayed Tmax (from a median of 0.75 hours to 3 hours) and 25% higher mean AUC0-&infin; compared with administration in the fasted state. Similar results were obtained for the active mono-demethylated metabolite.</p><p><u>Distribution</u></p><p>Ulipristal acetate is highly bound (&gt;98%) to plasma proteins, including albumin, alpha-l-acid glycoprotein, and high density lipoprotein.</p><p>Ulipristal acetate is a lipophilic compound and is distributed in breast milk, with a mean daily excretion of 13.35 &mu;g [0-24 hours], 2.16 &mu;g [24-48 hours], 1.06 &mu;g [48-72 hours], 0.58 &mu;g [72-96hours], and 0.31 &mu;g [96-120 hours].</p><p><em>In vitro </em>data indicate that ulipristal acetate may be an inhibitor of BCRP (Breast Cancer Resistance Protein) transporters at the intestinal level. The effects of ulipristal acetate on BCRP are unlikely to have any clinical consequences.</p><p>Ulipristal acetate is not a substrate for either OATP1B1 or OATP1B3. <u>Biotransformation/elimination</u></p><p>Ulipristal acetate is extensively metabolized to mono-demethylated, di-demethylated and hydroxylated metabolites. The mono-demethylated metabolite is pharmacologically active. <em>In vitro </em>data indicate that this is predominantly mediated by CYP3A4, and to a small extent by CYP1A2 and CYP2A6. The terminal half-life of ulipristal acetate in plasma following a single 30 mg dose is estimated to 32.4 &plusmn; 6.3 hours, with a mean oral clearance (CL/F) of 76.8 &plusmn; 64.0 L/h.</p><p><u>Special populations</u></p><p>No pharmacokinetic studies with ulipristal acetate have been performed in females with impaired renal or hepatic function.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.3&nbsp; Preclinical safety data</strong></p><p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, and genotoxicity. Most findings in general toxicity studies were related to its mechanism of action as a modulator of progesterone and glucocorticoid receptors, with antiprogesterone activity observed at exposures similar to therapeutic levels.</p><p>Information from reproductive toxicity studies is limited due to the absence of exposure measurement in these studies. Ulipristal acetate has an embryolethal effect in rats, rabbits (at repeated doses above 1 mg/kg) and in monkeys. At these repeated doses, the safety for a human embryo is unknown. At doses which were low enough to maintain gestation in the animal species, no teratogenic effects were observed.</p><p>Carcinogenicity studies (in rats and mice) showed that ulipristal acetate is not carcinogenic.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.1&nbsp; </strong><strong>List of excipients</strong></p><p>Tablet core:<br />Lactose monohydrate<br />Pregelatinised starch<br />Sodium starch glycolate Type (A)<br />magnesium stearate<br />Purified water</p><p>Coating:<br />Hypromellose (E464)<br />Hydroxypropylcellulose (E463)<br />Stearic acid (E570)<br />Talc (E553b)<br />Titanium Dioxide (E171)<br />Purified water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong>Store in original package in order to protect from light.</p><p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC-PVDC-Aluminium blister of 1 tablet.</p><p>The carton contains one transparent blister.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aspen Healthcare Malta Limited
89, Level 0
Triq is-Siggiewi
Is-Siggiewi SGW 2021
Malta

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Date of revision: February 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>